Fennec Pharmaceuticals Q3 2026 net product sales rise 56% to $19.4 million
FROM THE WIRE · GLOBENEWSWIRE.COM
~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~ ~ Third Quarter 2026 Non-GAAP Adjusted EBITDA of $5.8 Million ~ ~ With $6.7 Million in Positive Cash Flow from Operations, Cash Position in the Third Quarter 2026 Grew to $48.7 Million ~ ~ Record…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong revenue growth and rising cash position may interest investors in the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Net product sales rose 56% year over year.
- 02Non-GAAP adjusted EBITDA was $5.8 million.
- 03The cash position grew to $48.7 million.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets